Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells

Circulation Research

Volumn 83, Issue 9, 1998, Pages 952-959

  Chen, Xi Lin ^a   Tummala, Pradyumna E ^a   Olbrych, Matthew T ^a   Alexander, R Wayne ^a   Medford, Russell M ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AtheroGenics Inc   (United States)

Author keywords

Angiotensin II; AT1 receptor; Monocyte chemoattractant protein 1; Vascular smooth muscle cell

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANTIOXIDANT; HYDROGEN PEROXIDE; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROTEIN TYROSINE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; GENE EXPRESSION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

EID: 0032476632     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.83.9.952     Document Type: Article

References (64)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181-190.
3. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkeater DC, Laks H, Fogelman AM. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;2039-2047.
4. Randolph GJ, Furie MB. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J Immunol. 1995;155:3610-3618.
5. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 1993;24:534-539.
6. Nelken N, Coughlin SR, Gorden D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88:1121-1127.
7. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155-161.
8. Doyle AE. Hypertension and vascular disease. J Cardiovasc Pharmacol. 1992;19:S7-S10.
9. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
10. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993;329:616-619.
11. Alderman MH. Plasma renin activity and coronary heart disease: are they related? Curr Opin Nephrol Hypertens. 1995;4:201-203.
12. Cambien F, Poirer O, Lecerf L, Evens A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Richard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
13. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem S, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;:240:1173-1178.
14. Pitt B. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am Heart J. 1994;128:1328-1332.
15. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;12:327-331.
16. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992;20:473-477.
17. Andersson RG, Jacobsson L, Persson K. Angiotensin converting enzyme inhibitors and atherosclerosis. J Physiol Pharmacol. 1994;45:13-25.
18. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl 5):S65-S72.
19. Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: a comparative study with captopril. Circulation. 1996;93:333-339.
20. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
21. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
22. Chen XL, Tummala PE, Obrych MT, Medford RM. Oxidation-reduction and proteasome dependent activation of monocyte chemotactic protein-1 gene expression in human vascular cells. Circ Res. 1996;94:1276. Abstract.
23. Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlondorff D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G: evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest. 1993;92:1564-1571.
24. Evans GA, Garcia GG, Erwin R, Howard OM, Farrar WL. Pervanadate stimulates the effects of interleukin-2 (IL-2) in human T cells and provides evidence for the activation of two distinct tyrosine kinase pathways by IL-1. J Biol Chem. 1994;269:23407-23412.
25. Griendling KK, Taubman MB, Akers M, Mendlowitz M, Alexander RW. Characterization of phosphatidylinositol-specific phospholipase C from cultured vascular smooth muscle cells. J Biol Chem. 1991; 266:15498-15504.
26. Christensen PJ, Rolfe MW, Staniford TJ, Burdick MD, Toews GB, Strieter RM. Characterization of the production of monocyte chemoattractant protein-1 and IL-8 in an allogeneic immune response. J Immunol. 1993;151:1205-1213.
27. Chen XL, Tummala PE, Olliff L, Medford RM. E-selectin gene expression in vascular smooth muscle cells: evidence for a tissue-specific repressor protein. Circ Res. 1997;80:305-311.
28. 2 for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
29. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule-1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci. U S A 1996;93:9114-9119.
30. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res. 1995;76:980-986.
31. Marrero MB, Paxton WG, Schieffer B, Ling BN, Bernstein KE. Angiotensin II signaling events mediated by tyrosine phosphorylation. Cell Signal. 1996;8:21-26.
32. 2+ influx. Atherosclerosis. 1996;121:119-127.
33. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
34. Duff JL, Marrero MB, Paxton WG, Schieffer B, Bernstein KE, Berk BC. Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Cardiovasc Res. 1995;30:511-517. Review.
35. Liao DF, Duff JL, Daum G, Pelech SL, Berk BC. Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells: role of Raf. Circ Res. 1996;79:1007-1014.
36. Schorb W, Conrad KM, Singer HA, Dostal DE, Baker KM. Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. J Mol Cell Cardiol. 1995;27:1151-1160.
37. Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem. 1995;270:13585-13588.
38. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753-757.
39. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in platelet-derived grown factor-stimulated vascular smooth muscle cells. Circ Res. 1992;70:314-325.
40. Satriano JA, Hora K, Shan Z, Stanley ER, Mori T, Schlondorff D. Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-γ, tumor necrosis factor-α, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol. 1993;150:1971-1978.
41. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga J, Kawamoto S, Ishigatsubo Y, Okubo T. NF-κB and Sp1 regulate transcription of human monocyte chemoattractant protein-1 gene. J Immunol. 1994;153:2052-2063.
42. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-jun, c-fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem. 1995;270:22129-22134.
43. Rao GN, Lassegue B, Alexander RW, Griendling KK. Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells. Biochem J. 1994;299:197-201.
44. Rao GN, Alexander RW, Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-fos, c-jun, and c-myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest. 1995;96:842-847.
45. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 1993;12:2005-2015.
46. Li J, Brasier AR. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-κB p65) transcriptional factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol. 1996;10:252-264.
47. Shin WS, Hong YH, Peng HB, De Calerina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma: the role of constitutive NF-κB activity. J Biol Chem. 1996;271:11317-11324.
48. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthsarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett. 1993;334:170-174.
49. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. VCAM-1 gene transcription and expression is regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866-1874.
50. Weber C. Involvement of tyrosine phosphorylation in endothelial adhesion molecule induction. Immunol Res. 1996;15:30-37.
51. Geng Y, Zhang B, Lotz M. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J Immunol. 1993;151:6692-6700.
52. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1996;74:589-607. Review.
53. Hirano M, Osada S, Aoki T, Hosaka M, Inoue J, Ohno S. MEK kinase is involved in tumor necrosis factor α-induced NF-κB activation and degradation of IkB-a. J Biol Chem. 1996;271:13234-13238.
54. Crews CM, Alessandrini A, Erickson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 1992;258:478-480.
55. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995;270:14843-14846.
56. Duff JL, Berk BC, Corson MA. Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinase in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1992;188:257-264.
57. Duff JL, Minia BP, Berk BC. Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells: effect of actinomycin D and antisense oligonucleotides. J Biol Chem. 1995;270:7161-7166.
58. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GS, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
59. Capers QI, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor WR. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 1997;30:1397-1402.
60. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A. Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension. 1995;25:132-138.
61. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension. 1991;18:132-141.
62. Poon M, Hsu WC, Bogadanov VY, Taubman MB. Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am J Pathol. 1996;149:307-317.
63. Wenzel UO, Fouqueray B, Grandaliano G, Kim YS, Karamitsos C, Valente AJ, Abboud HE. Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. Circ Res. 1995;77:503-509.
64. Chen XL, Tummala PE, Olbrych M, Lausen JB, Harrison DG, Medford RM. Direct activation of aortic monocyte chemoattractant protein-1 gene expression in vivo and ex vivo by angiotensin II in experimental hypertension. Circulation. 1997;96(suppl I):I-285. Abstract.